Provention Bio Inc. (NASDAQ: PRVB) is 126.58% higher on its value in year-to-date trading and has touched a low of $3.18 and a high of $24.23 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PRVB stock was last observed hovering at around $23.91 in the last trading session, with the day’s gains setting it 0.04% off its average median price target of $25.00 for the next 12 months. It is also 4.2% off the consensus price target high of $25.00 offered by 5 analysts, but current levels are -26.05% lower than the price target low of $19.00 for the same period.
Currently trading at $23.95, the stock is 124.48% and 144.25% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.8 million and changing 0.17% at the moment leaves the stock 246.48% off its SMA200. PRVB registered 243.12% gain for a year compared to 6-month gain of 359.69%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock witnessed a 139.74% loss in the last 1 month and extending the period to 3 months gives it a 148.70%, and is 230.34% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.81% over the week and 5.22% over the month.
Provention Bio Inc. (PRVB) has around 82 employees, a market worth around $2.26B and $2.80M in sales. Distance from 52-week low is 651.96% and -1.16% from its 52-week high. The company has generated returns on investments over the last 12 months (-103.50%).
Provention Bio Inc. (PRVB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Provention Bio Inc. (PRVB) is a “Hold”. 5 analysts offering their recommendations for the stock have an average rating of 1.60, where 4 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Provention Bio Inc. is expected to release its quarterly report on 05/04/2023.The EPS is expected to grow by 3.50% this year
Provention Bio Inc. (PRVB) Top Institutional Holders
The shares outstanding are 83.12M, and float is at 81.80M with Short Float at 10.02%.
Provention Bio Inc. (PRVB) Insider Activity
A total of 22 insider transactions have happened at Provention Bio Inc. (PRVB) in the last six months, with sales accounting for 12 and purchases happening 10 times. The most recent transaction is an insider sale by Leon Francisco, the company’s Chief Scientific Officer. SEC filings show that Leon Francisco sold 25,985 shares of the company’s common stock on Feb 13 at a price of $10.04 per share for a total of $0.26 million. Following the sale, the insider now owns 1.57 million shares.
Provention Bio Inc. disclosed in a document filed with the SEC on Feb 13 that Palmer Ashleigh (Director and CEO) sold a total of 25,835 shares of the company’s common stock. The trade occurred on Feb 13 and was made at $10.04 per share for $0.26 million. Following the transaction, the insider now directly holds 2.57 million shares of the PRVB stock.
Still, SEC filings show that on Feb 10, Leon Francisco (Chief Scientific Officer) disposed off 50,000 shares at an average price of $10.11 for $0.51 million. The insider now directly holds 1,573,000 shares of Provention Bio Inc. (PRVB).
Provention Bio Inc. (PRVB): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -12.55% down over the past 12 months. Eli Lilly and Company (LLY) is 19.63% up on the 1-year trading charts.
